Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03404648 · ClinicalTrials.gov registry record · Phase 3
Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI
A Phase 3 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 19
- Enrollment target
NCT03404648: Completed Phase 3 study, sponsored by Mayo Clinic.
NCT03404648 is a Phase 3 study that has completed, run by Mayo Clinic. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03404648, a Phase 3 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if a PET/MR scan in combination with standard MRI and CT scans can improve the early detection and treatment of patients with prostate cancer.
Interventions
- DRUG Gadobutrol
- DRUG C-11 choline PET tracer
- DEVICE PET/MR scanner
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2017-11-01 |
| Est. Completion | 2020-01-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03404648
The ClinicalTrials.gov registry entry for NCT03404648 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gadobutrol is the first listed.
NCT03404648 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03404648 about?
NCT03404648 is a clinical study titled "Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI". The purpose of this study is to find out if a PET/MR scan in combination with standard MRI and CT scans can improve the early detection and treatment of patients with prostate cancer.
What is the current status of trial NCT03404648?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 19 participants. The study started on 2017-11-01. Estimated completion is 2020-01-23.
What interventions are being tested in trial NCT03404648?
The interventions under investigation include: Gadobutrol (DRUG), C-11 choline PET tracer (DRUG), PET/MR scanner (DEVICE).
Who is sponsoring clinical trial NCT03404648?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.